Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
Acceptable references to establish first/second/third line treatment
-
In a disease state that does not have authoritative Canadian consensus guidelines, could a CDA (previously CADTH) Provisional Funding Algorithm be used to support which products are recommended to be used first-line, second-line, third-line, etc. Providing this as an example: https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0047_Multiple_Myeloma.pdf.
-
In a disease state that does not have authoritative Canadian consensus guidelines, could a CDA (previously CADTH) Provisional Funding Algorithm be used to support which products are recommended to be used first-line, second-line, third-line, etc. Providing this as an example: https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0047_Multiple_Myeloma.pdf.
Good Morning, @maryssa
Historically, as confirmed by the provided document (see Background, paragraph 2 copy “Note that provisional funding algorithms are not treatment algorithms; they are neither meant to detail the full clinical management…”), these documents are not intended to be treatment algorithms. However, Canada's Drug Agency (CDA-AMC) has an expanded mandate and role, including improving medication prescribing practices. We will reach out to CDA to discuss whether their new mandate impacts PAAB review. Stay tuned.
-
Thanks Jennifer!
In the absence of authoritative Canadian consensus guidelines, is there another reference type you can recommend to support which products are recommended to be used first-line, second-line, third-line, etc?
